Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

This review provides the feasible literature on drug discovery through ML tools and
techniques that are enforced in every phase of drug development to accelerate the research …

Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …

Drug discovery and development pipelines are long, complex and depend on numerous
factors. Machine learning (ML) approaches provide a set of tools that can improve discovery …

The advancement of precision medicine in medical care has led behind the conventional
symptom-driven treatment process by allowing early risk prediction of disease through …

KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been
achieved over the past two decades, increasing our understanding of the disease biology …

Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …